Health‐related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study
- 30 July 2007
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 57 (6) , 1050-1057
- https://doi.org/10.1002/art.22887
Abstract
Objective To evaluate the impact of adalimumab on health‐related quality of life (HRQOL) in patients with active ankylosing spondylitis (AS). Methods Patients ≥18 years enrolled in the Adalimumab Trial Evaluating Long‐Term Efficacy and Safety in Ankylosing Spondylitis, a randomized controlled study, were randomly assigned to receive either adalimumab 40 mg subcutaneously or placebo every other week for 24 weeks. ASsessment of Ankylosing Spondylitis (ASAS) International Working Group criteria were used to evaluate clinical efficacy. HRQOL outcomes were assessed using the Short Form 36 (SF‐36) Health Survey and Ankylosing Spondylitis Quality of Life (ASQoL) Questionnaire. Results A total of 315 patients enrolled (208 in the adalimumab group and 107 in the placebo group). Patients in the adalimumab group showed significant improvements in SF‐36 Physical Component Summary (PCS) and ASQoL scores versus placebo at weeks 12 and 24 (P < 0.001). The observed differences between adalimumab and placebo patients exceeded the a priori minimum important difference (MID) at the group level, and significantly more adalimumab‐treated patients achieved improvements greater than the MID on the patient level. These data suggest the HRQOL improvements were clinically meaningful. No differences were observed in SF‐36 Mental Component Summary (MCS) scores. Significant differences favoring adalimumab were observed for SF‐36 domains physical function, bodily pain, role‐physical, general health, vitality, social function, and role–emotional. There was significant association between HRQOL improvements (measured by SF‐36 PCS and MCS, and ASQoL scores) and ASAS clinical responses (P < 0.001). Conclusion Adalimumab significantly improved physical health status and overall HRQOL through 24 weeks in patients with active AS.Keywords
This publication has 29 references indexed in Scilit:
- Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2006
- ASAS/EULAR recommendations for the management of ankylosing spondylitisAnnals of the Rheumatic Diseases, 2006
- Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trialArthritis & Rheumatism, 2005
- Health status of patients with ankylosing spondylitis: a comparison with the general populationAnnals of the Rheumatic Diseases, 2004
- Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trialArthritis & Rheumatism, 2004
- Functional disability and quality of life in patients with ankylosing spondylitisRheumatology International, 2003
- Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trialArthritis & Rheumatism, 2003
- Work status and productivity costs due to ankylosing spondylitis: comparison of three European countriesAnnals of the Rheumatic Diseases, 2002
- QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITISRheumatic Disease Clinics of North America, 1998
- Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitisArthritis & Rheumatism, 1995